ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD20 Antibody-drug Conjugate TRS005

Also written as “TRS005” and “Recombinant CD20 monoclonal antibody-MMAE conjugte for injection”.

Its studies are mostly in Lymphoma, Large B-Cell, Diffuse, led by Zhejiang Teruisi Pharmaceutical.

Drug pageAnti-CD20 Antibody-drug Conjugate TRS005: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Mar 14, 20253 company-led studies, 3 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zhejiang Teruisi Pharmaceutical33 open or runningphase 2since Mar 14, 2025May 19, 2022Jan 2027phase 2 · NCT06886139

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 19, 2022First study: phase 1 study in CD20-positive B-cell Non-Hodgkin LymphomaFirst studyNCT05395533 · 147 enrolled · China
  2. Mar 14, 2025Phase 2 study in CD20-positive Diffuse Large B-Cell LymphomaNCT06886139 · 139 planned · China
  3. Jun 13, 2025Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT07035379 · 66 planned · China

Ahead

  1. Jan 2027Primary completion: phase 2 study in CD20-positive Diffuse Large B-Cell LymphomaNCT06886139

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07035379Lymphoma, Large B-Cell, Diffuse · China2Not yet recruitingSep 1, 202666
NCT06886139CD20-positive Diffuse Large B-Cell Lymphoma · China2Not yet recruitingJan 2027139
NCT05395533CD20-positive B-cell Non-Hodgkin Lymphoma · China1Active, not recruitingJul 31, 2025147

How it is read

Names in the registry

  • “TRS005”, 2 entries
  • “Recombinant CD20 monoclonal antibody-MMAE conjugte for injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.